Skip to content

Digital precision treatment management platform for the whole perioperative management plan of patients undergoing segmentectomy for early lung cancer

Digital precision treatment management platform for the whole perioperative management plan of patients undergoing segmentectomy for early lung cancer

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2300072946
Enrollment
Unknown
Registered
2023-06-28
Start date
2023-07-01
Completion date
Unknown
Last updated
2023-07-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

non-small cell lung cancer

Interventions

treatment group:Using 3D reconstruction services for surgical planning and using digital therapy software for postoperative 30d symptom management and rehabilitation
control group:Using 3D reconstruction services for surgical planning and postoperative management and rehabilitation based on current clinical practice

Sponsors

Department of Thoracic Surgery, West China Hospital, Sichuan University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 75 Years

Inclusion criteria

Inclusion criteria: 1) Aged 18-75 years old; 2) Patients who plan to undergo minimally invasive segmentectomy; 3) The measured FEV1 value of the preoperative pulmonary function test is greater than or equal to 1.2L and greater than or equal to 60% of the predicted value; 4) Smartphones can be used to fill in Electronic questionnaire and signed informed consent; 5) Using lung three-dimensional reconstruction for surgical planning and treatment

Exclusion criteria

Exclusion criteria: 1) The preoperative smoking cessation time is less than 2 weeks; 2) The preoperative PS score of the patient is greater than 1 point; 3) Has received neoadjuvant therapy; 4) Previously received thoracic surgery; 5) Inability to move due to limb dysfunction; 6) Continuous use of systemic corticosteroids within 1 month before surgery; 7) Any toxicity resolved by previous treatment is greater than CTCAE grade 1

Design outcomes

Primary

MeasureTime frame
MDASI-LC scale symptom burden score;?FEV1%;FEV1;FVC;FEV1/FVC;

Secondary

MeasureTime frame
?FEV1%;FEV1;FVC;FEV1/FVC;adverse event rate;hospital readmissions rate;ICER;patient satisfaction score;

Countries

China

Contacts

Public ContactJiandong Mei

Department of Thoracic Surgery, West China Hospital, Sichuan University

jiandongmei@aliyun.com+86 189 8060 1762

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026